Humbert, M., Labrune, P., Sitbon, O. , Le Gall, C., Callebert, J., Hervé, P., Samuel, D., Machado, R., Trembath, R., Drouet, L., Launay, J. M. and Simonneau, G. (2002) Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. The European Respiratory Journal: official journal of the European Society for Clinical Respiratory Physiology, 20 (1). pp. 59-65. ISSN 0903-1936
Full content URL: http://dx.doi.org/10.1183/09031936.02.00258702
Documents |
|
![]() |
PDF
Machado_ERJ2002.pdf - Whole Document Restricted to Repository staff only 94kB |
Item Type: | Article |
---|---|
Item Status: | Live Archive |
Abstract
A case of pulmonary arterial hypertension in a patient with type-Ia glycogen-storage disease, a rare autosomal recessive disorder caused by a deficiency of glucose-6-phosphatase is reported in this study. It has been suggested that the occurrence of pulmonary arterial hypertension in type-Ia glycogen-storage disease could be due to an abnormal production of vasoconstrictive amines such as serotonin. To test this hypothesis, plasma serotonin concentrations were prospectively measured in 13 patients with type-Ia glycogen-storage disease, one patient with severe pulmonary hypertension and type-Ia glycogen-storage disease, 16 patients displaying severe pulmonary arterial hypertension, and 26 normal healthy controls. Elevated plasma serotonin concentrations were found in patients with either severe pulmonary arterial hypertension (38.8+/-7.3 nmol x L(-1)) or type-Ia glycogen-storage disease (36.8+/-11.5 nmol x L(-1)), as compared with controls (8.8+/-0.6 nmol x L(-1), p<0.001). Plasma serotonin was dramatically elevated in the patient with type-Ia glycogen-storage disease and pulmonary arterial hypertension (113.4 nmol x L(-1)). It is concluded that type-Ia glycogen-storage disease may be another condition in which abnormal handling of serotonin is one event in a multistep process leading to severe pulmonary arterial hypertension.
Additional Information: | A case of pulmonary arterial hypertension in a patient with type-Ia glycogen-storage disease, a rare autosomal recessive disorder caused by a deficiency of glucose-6-phosphatase is reported in this study. It has been suggested that the occurrence of pulmonary arterial hypertension in type-Ia glycogen-storage disease could be due to an abnormal production of vasoconstrictive amines such as serotonin. To test this hypothesis, plasma serotonin concentrations were prospectively measured in 13 patients with type-Ia glycogen-storage disease, one patient with severe pulmonary hypertension and type-Ia glycogen-storage disease, 16 patients displaying severe pulmonary arterial hypertension, and 26 normal healthy controls. Elevated plasma serotonin concentrations were found in patients with either severe pulmonary arterial hypertension (38.8+/-7.3 nmol x L(-1)) or type-Ia glycogen-storage disease (36.8+/-11.5 nmol x L(-1)), as compared with controls (8.8+/-0.6 nmol x L(-1), p<0.001). Plasma serotonin was dramatically elevated in the patient with type-Ia glycogen-storage disease and pulmonary arterial hypertension (113.4 nmol x L(-1)). It is concluded that type-Ia glycogen-storage disease may be another condition in which abnormal handling of serotonin is one event in a multistep process leading to severe pulmonary arterial hypertension. |
---|---|
Keywords: | Pulmonary arterial hypertension, Serotonin |
Subjects: | C Biological Sciences > C700 Molecular Biology, Biophysics and Biochemistry |
Divisions: | College of Science > School of Life Sciences |
ID Code: | 6326 |
Deposited On: | 01 Oct 2012 16:51 |
Repository Staff Only: item control page